Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0677481 (
urinary frequency
)
1,126
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Overactive bladder (OAB) is characterised by the storage symptoms of urgency, with or without urge incontinence, and usually with
urinary frequency
and nocturia. OAB is a common condition that affects people of all ages within society. It has an estimated prevalence of 16% and is known to adversely affect quality of life (QOL). Assessment of the QOL of patients is important to understanding both the burden of disease and improvement after treatment. In clinical practice, the physician's assessment of the disease burden of OAB has been shown to be inaccurate and non-reproducible. Psychometrically robust self-completion questionnaires provide a valid, reproducible and rapid assessment of patient-reported disease impact that can elicit the impact of symptoms, and they are also useful for the evaluation of the efficacy of an intervention. Many different questionnaires have been developed to assess the QOL impact of OAB. Generic instruments measure very broad aspects of health and are suitable for a wide range of patient groups and general population screening. They can be applied to patients with any medical condition and provide a measure of morbidity but are less sensitive to clinically relevant change in conditions such as OAB.
Condition
-specific questionnaires offer greater sensitivity and responsiveness to change in the assessment of QOL of specific patient groups. Single-item global assessment questionnaires are useful in conditions such as OAB that have multiple and varied symptoms, and reflect an individual's needs, concerns and values. Patient-derived outcome measures are used in real-world clinical practice, clinical trials, health economic research and healthcare planning.
...
PMID:Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments. 1724 55
Ductal adenocarcinoma of the prostate was initially described in 1967 by Melicow and Patcher. It was given the erroneous name endometrioid carcinoma, however, further studies confirmed the prostatic origin of this tumor. Currently
DAP
is classified as a histological variant of prostatic carcinoma. Compared with "classic" acinar carcinoma of the prostate,
DAP
is a rare histological finding. It's prevalence in prostatectomy and biopsy specimens varies from less than 1% for pure ductal adenocarcinoma up to 5% for mixed
DAP
. Because of its typical periurethral location, the tumor usually manifests itself clinically with urinary obstruction, urinary urgency,
urinary frequency
and hematuria.
DAP
is associated with more aggressive natural history and worse prognosis than pure AA - patients presented at more advanced stage, with poorly differentiated and distant disease.
DAP
has a tendency to spread to regional lymph nodes, axial skeleton, and visceral organs. We report a case of a 90-year old man who presented to our clinic with acute urinary retention and gross hematuria. He underwent suprapubic transvesical adenomectomy to diminish the urinary obstruction. The pathological examination of the specimens revealed a dominant focus of
DAP
, which was located near the intraprostatic urethra and a coexisting, smaller component of "classic" acinar adenocarcinoma.
...
PMID:An incidentally diagnosed prostatic ductal adenocarcinoma. 2457 20